Search: onr:"swepub:oai:DiVA.org:uu-342674" >
Neuroendocrine tumo...
Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion : a retrospective study
-
- Antonodimitrakis, Pantelis Clewemar (author)
- Uppsala universitet,Endokrin tumörbiologi
-
- Olofsson, Helena (author)
- Uppsala universitet,Klinisk och experimentell patologi
-
- Grimelius, Lars (author)
- Uppsala universitet,Experimentell och klinisk onkologi
-
show more...
-
- Sundin, Anders, 1954- (author)
- Uppsala universitet,Radiologi
-
- Wassberg, Cecilia (author)
- Uppsala universitet,Radiologi
-
- Granberg, Dan (author)
- Uppsala universitet,Onkologisk endokrinologi
-
- Skogseid, Britt (author)
- Uppsala universitet,Endokrin tumörbiologi
-
- Eriksson, Barbro (author)
- Uppsala universitet,Endokrin tumörbiologi
-
show less...
-
(creator_code:org_t)
- Future Medicine Ltd, 2017
- 2017
- English.
-
In: International Journal of Endocrine Oncology. - : Future Medicine Ltd. - 2045-0869 .- 2045-0877. ; 4:1, s. 9-22
- Related links:
-
https://www.futureme...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
show less...
Abstract
Subject headings
Close
- Aim: Vasoactive intestinal polypeptide producing neuroendocrine tumors are rare and cause severe hormonal symptoms. Patients/methods: Eighteen patients with vasoactive intestinal polypeptide producing neuroendocrine tumors were analyzed with reviews of medical records, radiology and tumor tissue specimens. Results: Twelve patients (67%) had liver metastases at diagnosis. Chemotherapy, somatostatin analogs and interferon were given as medical therapies. Streptozocin/5-fluorouracil produced an objective response in 40% of the evaluable patients. Somatostatin analogs gave a clinical/biochemical response in eight out of nine patients. Transarterial embolization of the liver and peptide receptor radionuclide therapy was given to refractory cases. Sixteen patients died during the observation period. The median overall survival from diagnosis was 102 months. Conclusion: Systemic chemotherapy and somatostatin analogs should be given in cases of advanced disease or for hormonal symptoms.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- chemotherapy
- IFN-α
- neuroendocrine tumors
- pancreas
- somatostatin analogs
- survival
- vasoactive intestinal polypeptide
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database